BIOGEN INC. — Director's Dealing 2022

Apr 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2022-04-01

Reporting Person: Murphy Nicole (Head of Pharm Ops and Tech)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-01	Common Stock	M	239	—	Acquired	1896.89	Direct
2022-04-01	Common Stock	F	84	$210.65	Disposed	1812.89	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-01	Restricted Stock Unit	$0	M	239	Disposed	2024-04-01	Common Stock (239)	Direct

Footnotes

F1: Each restricted stock unit is converted to one share of common stock upon vesting.

F2: This award was granted to the reporting person on April 1, 2021 and vested with respect to 239 shares on April 1, 2022. The remaining portion of the award vests in equal installments on each of the second and third anniversary of the grant date.